HYTEFLA
Live / Registered — Registered (as of 03 Dec 2024)
What this means for you
Registered since 03 Dec 2024. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79381491
- Registration number
- 7583045
- Mark type
- Stylized text
- Filed
- 01 Sept 2023
- Published for opposition
- 01 Oct 2024
- Registered
- 03 Dec 2024
- Attorney of record
- Scott D. Woldow
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for cardiovascular diseases, illnesses, and conditions; Pharmaceutical preparations for infusion conditions; pharmaceutical preparations for cardiovascular conditions and blood conditions, namely, novel, plasma derived apolipoprotein A-I conditions while undergoing infusion therapy; pharmaceutical preparations for novel apolipoprotein A-I infusion therapy to potentially reduce the risk of recurrent major adverse cardiovascular events (MACE) in patients within 90 days of an acute myocardial infarction (AMI) with a sustained benefit for 365 days; Pharmaceutical preparations for acute myocardial infarction (AMI); Pharmaceutical preparations for cardiovascular diseases; pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; pharmaceutical preparations and substances for the treatment of blood disorders; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema, HAE; Pharmaceutical preparations, namely, for the treatment of Hereditary Angioedema, HAE, respiratory diseases, acute respiratory distress syndrome, ARDS, Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD
Owner
- CSL Behring AG, CH
- CSL Behring AG, CH
- CSL Behring AG, CH
Prosecution history
- 18 Dec 2025 — FINAL DECISION TRANSACTION PROCESSED BY IB
- 13 Nov 2025 — GENERIC MADRID TRANSACTION SENT TO IB
- 13 Nov 2025 — GENERIC MADRID TRANSACTION CREATED
- 03 Dec 2024 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 03 Dec 2024 — REGISTERED-PRINCIPAL REGISTER
- 01 Oct 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 01 Oct 2024 — PUBLISHED FOR OPPOSITION
- 11 Sept 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 27 Aug 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 27 Aug 2024 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 27 Aug 2024 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 27 Aug 2024 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 11 Jun 2024 — REFUSAL PROCESSED BY IB
- 15 May 2024 — NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
- 15 May 2024 — REFUSAL PROCESSED BY MPU